-+ 0.00%
-+ 0.00%
-+ 0.00%
Peger Biopharmaceutical-B (02565) core product Paidacan® (vipernatide injection) was successfully included in the 2026 National Medical Insurance Drug List
Share
Listen to the news

According to Zhitong Finance App News, Peger Biopharmaceutical-B (02565) announced that the core innovative drug product Vipenatide injection (product name: Pidacan®, hereinafter referred to as “Paydacan®”) was successfully included in the “2026 National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue” recently announced by the National Health Security Administration.

The successful inclusion of Pidacang® in the national health insurance catalogue marks an important breakthrough in the entry of the Group's first commercialized innovative pharmaceutical product into the national medical insurance system. It is also an important milestone in the Group's transition from innovative R&D to large-scale commercialization.

Patacang® is a national Class 1 innovative drug independently developed by the Group. It is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) administered once a week. It was approved and marketed by the State Drug Administration in November 2025 to control blood sugar in adult type 2 diabetics.

As the Group's first innovative pharmaceutical product approved for marketing, Paidacan® has differentiated clinical characteristics such as treatment at the outset and no dose titration required. Key clinical findings show that Pidacan® can achieve continuous and stable blood sugar control and provide new treatment options for Chinese adult type 2 diabetics.



Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending